The Tech & Innovation Hub @ FUNanc1al
Tag: Genomics
The $60 Billion Cellular Gold Rush: Mapping the Market (and the Minefields)
Cell biology has gone from quiet labs to a $60B commercial engine. Here’s the FUNanc1al guide to the biggest trends, the smartest picks-and-shovels, and the biotech minefields investors should avoid.
Bioengineering, AI, and Designer Microbes: How to Love the Tech Without Losing Your Shirt.
Synthetic biology is transforming industries from aviation fuel to denim dye — but investors have learned the hard way that innovation doesn’t always equal profit. Here’s the fun, honest breakdown of where the science shines and where the stocks sink.
Will Gene Editing Stocks Ever Get Hot? If Not, Make Them CRISPR!
CRISPR Therapeutics (CRSP) just dropped jaw-dropping Phase 1 data: one IV treatment lowered triglycerides and LDL by up to 80%+ — safely. That’s not just biotech progress; it’s medical sci-fi turned reality. With insiders buying and gene-editing stocks heating up again, the question isn’t if CRISPR will change medicine — it’s whether it can change your portfolio.